March 25, 2019 5:46pm

As the pre-open post stated, “Oversold, there are many yet, for the lack of news – any momentum will be based on trading and sentiment which is considered a glass half full or half empty!”

Also, markets showed little reaction to the end of Special Prosecutor Mueller’s probe into the 2016 election, I believe many investors, traders and Americans are just fed up with the vitriol

Q4 and FY18 results: Cesca Therapeutics (KOOL)


Review the snapshot of the daily ‘workings” of the sector composite of cell and gene therapy companies.

That’s why my “quantamental” blend of styles; must become the “tool” for investors and traders to portfolio enrichment.


Markets and indexes:

  • The Dow closed up +14.51 points or +0.06% to 25,516.83
  • The S&P closed down -2.35 points or -0.08% to 2,798.36
  • The NASDAQ was down -5.13 points or -0.07% to 7,637.54



Market participants took Mueller’s investigation in stride. Attorney General William Barr said the probe didn’t find evidence that the Trump campaign “conspired or coordinated” with Russia to influence the 2016 presidential election. However, the investigation was inconclusive on whether President Donald Trump obstructed justice <MarketWatch>.

Sector equities eked out a small gain on Monday after news that the special counsel found no collusion with Russia on the part of President Trump.

Equities alternated between gains and losses for most of Monday as investors digested comments from Attorney General Barr.


Sector equities posting gains were:

  • SAGE (+$2.12), GBT (+$1.38), VYGR (+$1.17), RARE (+$1.08) and AXGN (+$1.01)

Crashing on Monday was:

  • RENE.L (-$2.00), QURE (-$1.48), CRSP (-$1.40), BLFS (-$0.75) and BOLD (-$0.68)


Indications were for another deep impact however …

My expectation of the upside was fulfilled by many of the “names” moving to the upside after Friday’s abysmal close.

I was surprised by BLUE, BLFS, CRSP and QURE were sent to a newer depth! But, don’t despair the week is still young …

WHAT is the sector about … REPAIR and REPLACE which will also be about their share pricing!

Q4 and FY18 results are dribbling out – Biostage (BSTG) is Thursday, 3/28.


Pre-open post, “reflex action, after a deep dive; there is usually an upswing! The oversold should rise but, futures are struggling after worries of a slowing global economy hit stocks on Friday.”


The advance/decline line scenario of 45 covered companies:  

  • The open was negative with the A/DL to 10/2, 2 flat and 1 acquired (AST);
  • The mid-day was barely positive with an A/DL of 22/21 and 2 flats and 1 acquired;
  • The close was positive with an A/DL of 23/21 and 0 flat and 1 acquired;


Tonight’s percentage (%) indicators: 

  • Range of the 23 upside was +0.06% (VCEL) to +6.51% (VYGR) while the 21 downside ranged from -0.05% (OSIR) to -15.20% (CUR -$0.091).

Volume stat: 

  • 5 out of the 23 upside had higher (than the 3 month average) volume
  • 8 out of the 21 downside experienced greater volume (than the 3 month average)

0 flat with 1 acquired: 1 (AST)


Q4 and FY18 results: Cesca Therapeutics (KOOL)

NO quarterly numbers …

  • KOOL incurred impairment charges of $33.1 M during FY18 compared to $300 K in FY17. The charges were the result of the impairment of intangible assets and goodwill relating to the clinical protocols acquired in the acquisition of Totipotent.

KOOL reported a FY18 net loss of $39.7 M or ($2.16) per share, based on 18.4 M shares outstanding; this compared to a net loss of $5.5 M or ($0.55) per share, based on 10 M shares outstanding for FY17.

KOOL had cash of approximately $2.4 M and a runway until Q4/19.


The iShares NASDAQ Biotechnology (IBB) indicator:

  • Monday was up +0.14%;
  • Friday was down -3.39%;
  • Thursday was down -1.07%;
  • Wednesday was down -0.59%;
  • Tuesday was down -0.06%;
  • Last Monday was down -0.31% after NOT indicating;


March sessions:

Monday closed POSITIVE with 21 decliners, 23 advancers, 0 flats and 1 acquired;

Friday closed NEGATIVE with 40 decliners, 2 advancers, 2 flats and 1 acquired;

Thursday closed POSITIVE with 12 decliners, 31 advancers, 1 flat and 1 acquired;

Wednesday closed NEGATIVE with 25 decliners, 18 advancers, 1 flat and 1 acquired;

Tuesday closed NEGATIVE with 22 decliners, 19 advancers, 3 flats and 1 acquired;

Monday (3/18) closed POSITIVE with 17 decliners, 27 advancers and 1 acquired;

Friday closed POSITIVE with 12 decliners, 32 advancers and 1 flat;

Thursday closed NEGATIVE with 30 decliners, 13 advancers and 2 flats;

Wednesday closed POSITIVE with 12 decliners, 30 advancers and 3 flats;

Tuesday closed POSITIVE with 13 decliners, 30 advancers and 2 flats;

Monday (3/11) closed POSITIVE with 7 decliners, 37 advancers and 1 flat;

Friday closed POSITIVE with 20 decliners, 22 advancers and 3 flats;

Thursday closed POSITIVE with 14 decliners, 29 advancers and 2 flats;

Wednesday closed NEGATIVE with 39 decliners, 5 advancers and 1 flat;

Tuesday (3/4) closed POSITIVE with 17 decliners, 23 advancers and 5 flats;

Monday (3/1) closed NEGATIVE with 24 decliners, 18 advancers and 3 flats;

Friday (3/1) closed POSITIVE with 11 decliners, 32 advancers and 2 flats;


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.